Memantine Zydus France (Memantine Hydrochloride)

Memantine is indicated for the symptomatic management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

• Alzheimer’s disease (mild to moderate): may help maintain cognitive performance and daily living activities.
• Alzheimer’s disease (moderate to severe): may support functional abilities and reduce behavioral symptoms.
• Alzheimer’s disease (early stage): may delay progression of memory loss and executive dysfunction.

• Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, may require dietary adjustment.
• Confusion: occasional disorientation, typically early in treatment.

Serious or Rare Side Effects

• Seizures: rare but may occur, particularly in patients with pre‑existing seizure disorders.
• Allergic reactions: rash, pruritus, or angioedema requiring medical attention.
• Hallucinations: visual or auditory disturbances, usually reversible.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, necessitating immediate discontinuation.

Before initiating memantine, consider the following safety measures.

• Renal impairment: adjust dose or avoid use in severe renal dysfunction.
• Hepatic impairment: monitor liver function tests and use with caution.
• Concomitant NMDA antagonists: avoid co‑administration to reduce additive toxicity.
• Blood pressure monitoring: watch for hypertension, especially in patients with cardiovascular disease.
• Discontinuation: do not stop abruptly; taper under medical supervision to minimize withdrawal effects.
• Store below 25°C: keep in the original pack, protect from moisture.

Memantine may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism can increase neuropsychiatric adverse events.
• Other NMDA antagonists (e.g., ketamine): additive risk of CNS effects.
• Potassium‑sparing diuretics (e.g., spironolactone): may raise serum potassium when renal function is compromised.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may blunt cognitive benefits of memantine.
• CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation.
• Antihypertensives: observe blood pressure for additive hypotensive effect.
• Proton‑pump inhibitors: may alter memantine absorption; assess therapeutic response.